Literature DB >> 12584225

Enhanced vasodilatation to endothelin antagonism in patients with compensated cirrhosis and the role of nitric oxide.

A Helmy1, D E Newby, R Jalan, P C Hayes, D J Webb.   

Abstract

BACKGROUND AND AIMS: Patients with advanced cirrhosis have systemic vasodilatation and increased nitric oxide (NO) production despite activated vasopressor systems, including the endothelin system. The aims of this study were to assess the contribution of endogenous endothelin 1 (ET-1) and NO to the maintenance of basal forearm vascular tone in patients with preascitic cirrhosis (n=7) and in age and sex matched healthy controls (n=7).
METHODS: Using venous occlusion plethysmography, forearm blood flow (FBF) responses to subsystemic locally active intra-arterial infusion of BQ-123 (a selective endothelin type A receptor (ET(A)) receptor antagonist; 10 nmol/min) were measured before and during application of an "NO clamp": a balanced co-infusion of L-N(G)-monomethyl-arginine (a selective NO synthase inhibitor) and sodium nitroprusside (an exogenous NO donor) to block endogenous NO production and restore NO mediated basal FBF, respectively.
RESULTS: L-NMMA infusion produced a reduction in FBF (p<0.001) which was similar in both groups. Before applying the "NO clamp", BQ-123 caused an increase in FBF in both groups (p<0.001) that was greater in patients with cirrhosis (p<0.01). During the "NO clamp", BQ-123 induced vasodilatation was abolished in controls and attenuated in patients (p<0.001) but remained significantly greater in patients with cirrhosis (p<0.01).
CONCLUSIONS: These findings indicate a greater ET(A) mediated contribution of endogenous ET-1 to the maintenance of basal forearm vascular tone in patients with preascitic cirrhosis. In addition, enhanced vasodilatation to ET(A) receptor antagonism in cirrhosis cannot be entirely attributed to NO release but is likely to be related to reversal of direct ET-1 mediated tone.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12584225      PMCID: PMC1773556          DOI: 10.1136/gut.52.3.410

Source DB:  PubMed          Journal:  Gut        ISSN: 0017-5749            Impact factor:   23.059


  46 in total

1.  Circulatory changes in chronic liver disease.

Authors:  J F MURRAY; A M DAWSON; S SHERLOCK
Journal:  Am J Med       Date:  1958-03       Impact factor: 4.965

2.  Endocannabinoids acting at vascular CB1 receptors mediate the vasodilated state in advanced liver cirrhosis.

Authors:  S Bátkai; Z Járai; J A Wagner; S K Goparaju; K Varga; J Liu; L Wang; F Mirshahi; A D Khanolkar; A Makriyannis; R Urbaschek; N Garcia; A J Sanyal; G Kunos
Journal:  Nat Med       Date:  2001-07       Impact factor: 53.440

3.  Effects of endothelium-derived nitric oxide on peripheral arteriolar tone in man.

Authors:  P Vallance; J Collier; S Moncada
Journal:  Lancet       Date:  1989-10-28       Impact factor: 79.321

4.  Non-invasive determination of cardiac output by Doppler echocardiography and electrical bioimpedance.

Authors:  D B Northridge; I N Findlay; J Wilson; E Henderson; H J Dargie
Journal:  Br Heart J       Date:  1990-02

5.  Influence of the degree of liver failure on systemic and splanchnic haemodynamics and on response to propranolol in patients with cirrhosis.

Authors:  A Braillon; P Cales; D Valla; D Gaudy; P Geoffroy; D Lebrec
Journal:  Gut       Date:  1986-10       Impact factor: 23.059

6.  Measuring forearm blood flow and interpreting the responses to drugs and mediators.

Authors:  N Benjamin; A Calver; J Collier; B Robinson; P Vallance; D Webb
Journal:  Hypertension       Date:  1995-05       Impact factor: 10.190

Review 7.  Why are circulating concentrations of endothelin-1 so low?

Authors:  C Frelin; D Guedin
Journal:  Cardiovasc Res       Date:  1994-11       Impact factor: 10.787

8.  Evidence for an endothelium-derived hyperpolarizing factor in the superior mesenteric artery from rats with cirrhosis.

Authors:  E Barriere; K A Tazi; J P Rona; F Pessione; J Heller; D Lebrec; R Moreau
Journal:  Hepatology       Date:  2000-11       Impact factor: 17.425

9.  Dose- and time-dependency of the dilator effects of the endothelin antagonist, BQ-123, in the human forearm.

Authors:  J R Berrazueta; K Bhagat; P Vallance; R J MacAllister
Journal:  Br J Clin Pharmacol       Date:  1997-12       Impact factor: 4.335

10.  Decreased vascular responsiveness to noradrenaline following regular ethanol consumption.

Authors:  L G Howes; J L Reid
Journal:  Br J Clin Pharmacol       Date:  1985-12       Impact factor: 4.335

View more
  18 in total

1.  Responses to endothelin-1 in patients with advanced cirrhosis before and after liver transplantation.

Authors:  A Helmy
Journal:  Gut       Date:  2004-03       Impact factor: 23.059

Review 2.  Role of endothelin in systemic and portal resistance in cirrhosis.

Authors:  P W Angus
Journal:  Gut       Date:  2006-09       Impact factor: 23.059

3.  Endothelin-1 contributes to maintenance of systemic but not portal haemodynamics in patients with early cirrhosis: a randomised controlled trial.

Authors:  D Tripathi; G Therapondos; J W Ferguson; D E Newby; D J Webb; P C Hayes
Journal:  Gut       Date:  2006-01-24       Impact factor: 23.059

4.  The role of endothelin A receptors in peripheral vascular control at rest and during exercise in patients with hypertension.

Authors:  Jesse C Craig; Ryan M Broxterman; D Taylor La Salle; James Cerbie; Stephen M Ratchford; Jayson R Gifford; Kanokwan Bunsawat; Ashley D Nelson; Amber D Bledsoe; David E Morgan; D Walter Wray; Russell S Richardson; Joel D Trinity
Journal:  J Physiol       Date:  2019-12-09       Impact factor: 5.182

Review 5.  Hepatosplanchnic circulation in cirrhosis and sepsis.

Authors:  Meghan Prin; Jan Bakker; Gebhard Wagener
Journal:  World J Gastroenterol       Date:  2015-03-07       Impact factor: 5.742

6.  Endothelin receptor antagonist TAK-044 arrests and reverses the development of carbon tetrachloride induced cirrhosis in rats.

Authors:  C Thirunavukkarasu; Y Yang; V M Subbotin; S A K Harvey; J Fung; C R Gandhi
Journal:  Gut       Date:  2004-07       Impact factor: 23.059

7.  Endogenous endothelin-1 and femoral artery shear rate: impact of age and implications for atherosclerosis.

Authors:  Joel D Trinity; Zachary Barrett-O'Keefe; Stephen J Ives; Garrett Morgan; Matthew J Rossman; Anthony J Donato; Sean Runnels; David E Morgan; Benjamin S Gmelch; Amber D Bledsoe; Russell S Richardson; D Walter Wray
Journal:  J Hypertens       Date:  2016-02       Impact factor: 4.844

8.  Increased endothelin receptor B and G protein coupled kinase-2 in the mesentery of portal hypertensive rats.

Authors:  Qing-Hong Du; Lin Han; Jun-Jie Jiang; Peng-Tao Li; Xin-Yue Wang; Xu Jia
Journal:  World J Gastroenterol       Date:  2013-04-07       Impact factor: 5.742

9.  Endothelin and vascular function in liver disease.

Authors:  K Moore
Journal:  Gut       Date:  2004-02       Impact factor: 23.059

Review 10.  Cardiopulmonary complications in chronic liver disease.

Authors:  Soren Moller; Jens H Henriksen
Journal:  World J Gastroenterol       Date:  2006-01-28       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.